Loss of function alterations in the cyclin dependent kinase inhibitor 2A (CDKN2A) locus are present in 25–35% of melanoma with a higher frequency in patients with a strong family history of melanoma, in comparison to those with sporadic melanoma, and are involved in the genesis of malignant cutaneous melanoma by generally occurring at the stage of dysplastic nevus [2,16,21,22]. Here, CDKN2A is linked to cutaneous melanoma.